Fiscal Year 2010 Annual Review of Rescue Inhaler Products

Oklahoma Health Care Authority
April 2011

Current Prior Authorization Criteria

The following tier list and criteria were effective during fiscal year 2010:

<table>
<thead>
<tr>
<th>Rescue Inhaler Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProAir® HFA</td>
</tr>
<tr>
<td>Proventil® HFA</td>
</tr>
<tr>
<td>Ventolin® HFA</td>
</tr>
</tbody>
</table>

**Approval Criteria:**
1. Approved or clinically accepted indication, and
2. Specific reason member cannot use all available tier one products.

**Additional Criteria for Xopenex®:**
1. In the prior authorization request, the prescriber should document why the member is unable to use racemic albuterol. For those members with asthma, members should also be utilizing inhaled corticosteroid (ICS) therapy for long-term control per NAEPP guidelines.
2. Dose of levalbuterol requested cannot be less than the racemic equivalent documented on the prior authorization request.

There is also a quantity limit of two inhalers per 30 days on all products:
- Proventil® HFA: 13.4g m
- Ventolin® HFA: 36 gm
- ProAir® HFA: 17gm
- Xopenex®: 30gm

Utilization of Rescue Inhaler Products

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Members</th>
<th>Claims</th>
<th>Paid</th>
<th>Paid/Claim</th>
<th>Perdiem</th>
<th>Units</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>54,632</td>
<td>115,184</td>
<td>$5,230,318.41</td>
<td>$45.41</td>
<td>$1.93</td>
<td>1,281,908</td>
<td>2,710,206</td>
</tr>
<tr>
<td>2010</td>
<td>69,119</td>
<td>150,399</td>
<td>$6,774,444.87</td>
<td>$45.04</td>
<td>$1.89</td>
<td>1,846,162</td>
<td>3,580,607</td>
</tr>
<tr>
<td>% Change</td>
<td>26.50%</td>
<td>30.60%</td>
<td>29.50%</td>
<td>-0.80%</td>
<td>-2.10%</td>
<td>44.00%</td>
<td>32.10%</td>
</tr>
<tr>
<td>Change</td>
<td>14,487</td>
<td>35,215</td>
<td>$1,544,126.46</td>
<td>-$0.37</td>
<td>-$0.04</td>
<td>564,254</td>
<td>870,401</td>
</tr>
</tbody>
</table>
### Utilization Details for FY 2010

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Brand Name</th>
<th>Claims</th>
<th>Members</th>
<th>Amount Paid</th>
<th>Claims/Members</th>
<th>Perdiem</th>
<th>% Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albuterol</td>
<td>PROAIR HFA AER</td>
<td>96,158</td>
<td>45,261</td>
<td>$4,473,474.09</td>
<td>2.12</td>
<td>$1.97</td>
<td>66.03%</td>
</tr>
<tr>
<td>Albuterol</td>
<td>VENTOLIN HFA AER</td>
<td>35,409</td>
<td>19,892</td>
<td>$1,375,996.12</td>
<td>1.78</td>
<td>$1.61</td>
<td>20.31%</td>
</tr>
<tr>
<td>Albuterol</td>
<td>PROVENTIL AER HFA</td>
<td>17,660</td>
<td>9,650</td>
<td>$857,810.93</td>
<td>1.83</td>
<td>$2.03</td>
<td>12.66%</td>
</tr>
<tr>
<td>Levalbuterol</td>
<td>XOPENEX AER HFA</td>
<td>1,172</td>
<td>458</td>
<td>$67,163.73</td>
<td>2.56</td>
<td>$2.29</td>
<td>0.99%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td>150,399</td>
<td>69,119</td>
<td>$6,774,444.87</td>
<td>2.18</td>
<td>$1.89</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

### Demographics of Members Utilizing Rescue Inhaler Products: FY 2010

- **Number of Members**
  - Age Groups
    - 00-09: 16,000
    - 10-19: 14,000
    - 20-34: 12,000
    - 35-49: 10,000
    - 50-64: 8,000
    - 65-79: 6,000
    - 80-94: 4,000
    - 95+: 2,000

- **Prescriber Specialties by Number of Claims: FY 2010**
  - **Family Practitioner**
  - **General Pediatrician**
  - **Nurse Practitioner (Other)**
  - **Physician Assistant**
  - **OHCA Non-Contracted Prescriber**
  - **General Practitioner**
  - **Internist**
  - **Emergency Medicine Practitioner**
  - **Obstetrician/Gynecologist**
  - **DDSD-NFM**
Utilization of Rescue Inhaler Products

There were a total of 1,580 petitions submitted for this PBPA category during fiscal year 2010. The following chart shows the status of the submitted petitions.

Status of Petitions during FY 2010

- Incomplete: 769 (49%)
- Approved: 790 (50%)
- Denied: 21 (1%)

Market News and Update

September 17, 2009 - The U.S. Food and Drug Administration advised consumers not to use certain respiratory medications purchased after Sept. 8, 2009 manufactured by Dey L.P., a subsidiary of Mylan Inc., because the medications might have been part of a shipment being transported on a tractor-trailer stolen in Tampa, Fla., on Sept. 8, 2009.

Conclusion and Recommendations

The College of Pharmacy recommends continued monitoring of this category.